Safety and immunogenicity of a chimeric vaccine for West Nile virus in aged subjects

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Evaluation of: Biedenbender R, Bevilacqua J, Gregg AM, Watson M, Dayan G. Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults. J. Infect. Dis. 203(1), 75-84 (2011). A recent Phase II clinical trial has demonstrated comparable safety and immunogenicity of ChimeriVax-WN02, a chimeric West Nile virus (WNV) vaccine candidate based on yellow fever 17D, in small cohorts of healthy adults aged 18-40, 41-64 and 65-80 years. Adults ≥65 years of age are an important target population for candidate WNV vaccines as they have a high risk for severe WNV neuroinvasive disease. The apparent safety and immunogenicity of ChimeriVax-WN02 in this population indicates that further development and clinical testing are justified.

Original languageEnglish (US)
Pages (from-to)601-604
Number of pages4
JournalExpert Review of Vaccines
Volume10
Issue number5
DOIs
StatePublished - May 2011

Fingerprint

West Nile Virus Vaccines
Safety
Yellow Fever
West Nile virus
Phase II Clinical Trials
Health Services Needs and Demand
Virus Diseases
Multicenter Studies
Placebos
Population
ChimeriVax

Keywords

  • adverse events
  • elderly
  • immunogenicity
  • safety
  • vaccine
  • West Nile virus

ASJC Scopus subject areas

  • Immunology
  • Drug Discovery
  • Pharmacology
  • Molecular Medicine

Cite this

Safety and immunogenicity of a chimeric vaccine for West Nile virus in aged subjects. / Beasley, David.

In: Expert Review of Vaccines, Vol. 10, No. 5, 05.2011, p. 601-604.

Research output: Contribution to journalArticle

@article{28726c2efea84c498f3c9c3c73cf7575,
title = "Safety and immunogenicity of a chimeric vaccine for West Nile virus in aged subjects",
abstract = "Evaluation of: Biedenbender R, Bevilacqua J, Gregg AM, Watson M, Dayan G. Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults. J. Infect. Dis. 203(1), 75-84 (2011). A recent Phase II clinical trial has demonstrated comparable safety and immunogenicity of ChimeriVax-WN02, a chimeric West Nile virus (WNV) vaccine candidate based on yellow fever 17D, in small cohorts of healthy adults aged 18-40, 41-64 and 65-80 years. Adults ≥65 years of age are an important target population for candidate WNV vaccines as they have a high risk for severe WNV neuroinvasive disease. The apparent safety and immunogenicity of ChimeriVax-WN02 in this population indicates that further development and clinical testing are justified.",
keywords = "adverse events, elderly, immunogenicity, safety, vaccine, West Nile virus",
author = "David Beasley",
year = "2011",
month = "5",
doi = "10.1586/erv.11.47",
language = "English (US)",
volume = "10",
pages = "601--604",
journal = "Expert Review of Vaccines",
issn = "1476-0584",
publisher = "Expert Reviews Ltd.",
number = "5",

}

TY - JOUR

T1 - Safety and immunogenicity of a chimeric vaccine for West Nile virus in aged subjects

AU - Beasley, David

PY - 2011/5

Y1 - 2011/5

N2 - Evaluation of: Biedenbender R, Bevilacqua J, Gregg AM, Watson M, Dayan G. Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults. J. Infect. Dis. 203(1), 75-84 (2011). A recent Phase II clinical trial has demonstrated comparable safety and immunogenicity of ChimeriVax-WN02, a chimeric West Nile virus (WNV) vaccine candidate based on yellow fever 17D, in small cohorts of healthy adults aged 18-40, 41-64 and 65-80 years. Adults ≥65 years of age are an important target population for candidate WNV vaccines as they have a high risk for severe WNV neuroinvasive disease. The apparent safety and immunogenicity of ChimeriVax-WN02 in this population indicates that further development and clinical testing are justified.

AB - Evaluation of: Biedenbender R, Bevilacqua J, Gregg AM, Watson M, Dayan G. Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults. J. Infect. Dis. 203(1), 75-84 (2011). A recent Phase II clinical trial has demonstrated comparable safety and immunogenicity of ChimeriVax-WN02, a chimeric West Nile virus (WNV) vaccine candidate based on yellow fever 17D, in small cohorts of healthy adults aged 18-40, 41-64 and 65-80 years. Adults ≥65 years of age are an important target population for candidate WNV vaccines as they have a high risk for severe WNV neuroinvasive disease. The apparent safety and immunogenicity of ChimeriVax-WN02 in this population indicates that further development and clinical testing are justified.

KW - adverse events

KW - elderly

KW - immunogenicity

KW - safety

KW - vaccine

KW - West Nile virus

UR - http://www.scopus.com/inward/record.url?scp=79957592934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957592934&partnerID=8YFLogxK

U2 - 10.1586/erv.11.47

DO - 10.1586/erv.11.47

M3 - Article

VL - 10

SP - 601

EP - 604

JO - Expert Review of Vaccines

JF - Expert Review of Vaccines

SN - 1476-0584

IS - 5

ER -